C4 Therapeutics Stock Today
| CCCC Stock | USD 4.55 0.36 8.59% |
Performance0 of 100
| Odds Of DistressLess than 45
|
C4 Therapeutics is trading at 4.55 as of the 28th of November 2024, a 8.59 percent increase since the beginning of the trading day. The stock's open price was 4.19. C4 Therapeutics has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for C4 Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 2nd of October 2020 | Category Healthcare | Classification Health Care |
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts. The company has 70.59 M outstanding shares of which 5.85 M shares are currently shorted by private and institutional investors with about 8.83 trading days to cover. More on C4 Therapeutics
Moving together with CCCC Stock
| 0.73 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.65 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
Moving against CCCC Stock
CCCC Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | Andrew MBA | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsC4 Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand C4 Therapeutics' financial leverage. It provides some insight into what part of C4 Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
C4 Therapeutics (CCCC) is traded on NASDAQ Exchange in USA. It is located in 490 Arsenal Way, Watertown, MA, United States, 02472 and employs 145 people. C4 Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 295.77 M. C4 Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 70.59 M outstanding shares of which 5.85 M shares are currently shorted by private and institutional investors with about 8.83 trading days to cover.
C4 Therapeutics currently holds about 307.78 M in cash with (106.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.29, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check C4 Therapeutics Probability Of Bankruptcy
Ownership AllocationC4 Therapeutics secures a total of 70.59 Million outstanding shares. The majority of C4 Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in C4 Therapeutics to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in C4 Therapeutics. Please pay attention to any change in the institutional holdings of C4 Therapeutics as this could imply that something significant has changed or is about to change at the company. Also note that almost two million one hundred sixty-seven thousand eighty-two invesors are currently shorting C4 Therapeutics expressing very little confidence in its future performance.
Check CCCC Ownership Details
CCCC Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Advisers, Llc | 2024-06-30 | 1.4 M | |
| Geode Capital Management, Llc | 2024-09-30 | 1.4 M | |
| Arrowmark Colorado Holdings, Llc (arrowmark Partners) | 2024-09-30 | 1.3 M | |
| Point72 Asset Management, L.p. | 2024-09-30 | 1.2 M | |
| Bain Capital Life Sciences Investors, Llc | 2024-09-30 | 1.1 M | |
| Two Sigma Investments Llc | 2024-09-30 | 828.5 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 737.8 K | |
| Tang Capital Management Llc | 2024-09-30 | 700 K | |
| Dimensional Fund Advisors, Inc. | 2024-09-30 | 578.9 K | |
| Wasatch Advisors Lp | 2024-09-30 | 5.7 M | |
| Ra Capital Management, Llc | 2024-09-30 | 4.9 M |
C4 Therapeutics Historical Income Statement
CCCC Stock Against Markets
C4 Therapeutics Corporate Management
| Paige Mahaney | Chief Officer | Profile | |
| Kelly Schick | Chief Officer | Profile | |
| Isabel Chiu | Senior Development | Profile | |
| Mr MBA | Chief Officer | Profile | |
| Andrew Hirsch | Pres CEO | Profile | |
| Leonard MD | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade CCCC Stock refer to our How to Trade CCCC Stock guide.You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of C4 Therapeutics. If investors know CCCC will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about C4 Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.71) | Revenue Per Share 0.522 | Quarterly Revenue Growth 0.387 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of C4 Therapeutics is measured differently than its book value, which is the value of CCCC that is recorded on the company's balance sheet. Investors also form their own opinion of C4 Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is C4 Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because C4 Therapeutics' market value can be influenced by many factors that don't directly affect C4 Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between C4 Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if C4 Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, C4 Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.